[
    {
        "molecule_name": "Ustekinumab",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "<10%",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-23 differs by not more than 10%, preferably by not more than 9%, more preferably by not more than 8%, even more preferably by not more than 7% and most preferably by not more than 5% from the binding of the reference product to IL-23.\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-12 differs by not more than 20%, preferably by not more than 15%, more preferably by not more than 12% and most preferably by not more than 10% from the binding of the reference product to IL-12.\nThe binding of the ustekinumab antibody produced by the method of the present invention to FcRn is essentially the same as that of the reference product, i.e. the dissociation constant K<sub>D </sub>for binding to FcRn differs by less than 10%, preferably by less than 8%, more preferably by less than 6% and most preferably by less than 4% from the dissociation constant K<sub>D </sub>of the reference product.\nThe inhibition of IFNγ production by the ustekinumab antibody produced by the method of the present invention differs by not more than 16%, preferably by not more than 14%, more preferably by not more than 12% and most preferably by not more from 10% from the inhibition of IFNγ production by the reference product.\n(i) binding to IL-23 differs from that of the reference product by not more than 10%;\n(ii) binding to IL-12 differs from that of the reference product by not more than 20%;\n(iii) binding to FcRn differs from that of the reference product by less than 10%;"
    },
    {
        "molecule_name": "Ustekinumab",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "<8%",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-23 differs by not more than 10%, preferably by not more than 9%, more preferably by not more than 8%, even more preferably by not more than 7% and most preferably by not more than 5% from the binding of the reference product to IL-23.\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-12 differs by not more than 20%, preferably by not more than 15%, more preferably by not more than 12% and most preferably by not more than 10% from the binding of the reference product to IL-12.\nThe binding of the ustekinumab antibody produced by the method of the present invention to FcRn is essentially the same as that of the reference product, i.e. the dissociation constant K<sub>D </sub>for binding to FcRn differs by less than 10%, preferably by less than 8%, more preferably by less than 6% and most preferably by less than 4% from the dissociation constant K<sub>D </sub>of the reference product.\nThe inhibition of IFNγ production by the ustekinumab antibody produced by the method of the present invention differs by not more than 16%, preferably by not more than 14%, more preferably by not more than 12% and most preferably by not more from 10% from the inhibition of IFNγ production by the reference product.\n(i) binding to IL-23 differs from that of the reference product by not more than 10%;\n(ii) binding to IL-12 differs from that of the reference product by not more than 20%;\n(iii) binding to FcRn differs from that of the reference product by less than 10%;"
    },
    {
        "molecule_name": "Ustekinumab",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "<6%",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-23 differs by not more than 10%, preferably by not more than 9%, more preferably by not more than 8%, even more preferably by not more than 7% and most preferably by not more than 5% from the binding of the reference product to IL-23.\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-12 differs by not more than 20%, preferably by not more than 15%, more preferably by not more than 12% and most preferably by not more than 10% from the binding of the reference product to IL-12.\nThe binding of the ustekinumab antibody produced by the method of the present invention to FcRn is essentially the same as that of the reference product, i.e. the dissociation constant K<sub>D </sub>for binding to FcRn differs by less than 10%, preferably by less than 8%, more preferably by less than 6% and most preferably by less than 4% from the dissociation constant K<sub>D </sub>of the reference product.\nThe inhibition of IFNγ production by the ustekinumab antibody produced by the method of the present invention differs by not more than 16%, preferably by not more than 14%, more preferably by not more than 12% and most preferably by not more from 10% from the inhibition of IFNγ production by the reference product.\n(i) binding to IL-23 differs from that of the reference product by not more than 10%;\n(ii) binding to IL-12 differs from that of the reference product by not more than 20%;\n(iii) binding to FcRn differs from that of the reference product by less than 10%;"
    },
    {
        "molecule_name": "Ustekinumab",
        "protein_target_name": "FcRn",
        "binding_metric": "Kd",
        "value": "<4%",
        "unit": null,
        "is_logarithmic": false,
        "raw_mentions": "Here are the extracted sentences that meet the criteria:\n\n\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-23 differs by not more than 10%, preferably by not more than 9%, more preferably by not more than 8%, even more preferably by not more than 7% and most preferably by not more than 5% from the binding of the reference product to IL-23.\nThe binding of the ustekinumab antibody produced by the method of the present invention to IL-12 differs by not more than 20%, preferably by not more than 15%, more preferably by not more than 12% and most preferably by not more than 10% from the binding of the reference product to IL-12.\nThe binding of the ustekinumab antibody produced by the method of the present invention to FcRn is essentially the same as that of the reference product, i.e. the dissociation constant K<sub>D </sub>for binding to FcRn differs by less than 10%, preferably by less than 8%, more preferably by less than 6% and most preferably by less than 4% from the dissociation constant K<sub>D </sub>of the reference product.\nThe inhibition of IFNγ production by the ustekinumab antibody produced by the method of the present invention differs by not more than 16%, preferably by not more than 14%, more preferably by not more than 12% and most preferably by not more from 10% from the inhibition of IFNγ production by the reference product.\n(i) binding to IL-23 differs from that of the reference product by not more than 10%;\n(ii) binding to IL-12 differs from that of the reference product by not more than 20%;\n(iii) binding to FcRn differs from that of the reference product by less than 10%;"
    }
]